Summary:
- The article examines the medical trend of "microdosing" semaglutide (Ozempic), a practice involving the off-label use of doses lower than those clinically approved for weight management or diabetes.
- It provides expert clinical commentary on the physiological mechanisms of GLP-1 receptor agonists, the risks of self-administering non-standard doses, and the importance of medical supervision to mitigate potential side effects like gastrointestinal distress and muscle loss.